BACKGROUND: In chronic diarrhea patients, massive over-reporting symptom-based criteria for functional bowel disorders are pitfalls. There is currently no objective biomarker that may provide a correct correlation with the severity of chronic diarrhea. To clarify the role of fibroblast growth factor-19 (FGF-19) as a biomarker of objective measurements of the severity of diarrhea in comparison with a patientreported outcome, based on the Bristol Stool Form (BSF) Scale. METHODS: Consecutive 100 patients with chronic diarrhea underwent standard investigations with laboratory tests, fecal calprotectin (FC), endoscopy with biopsies, and serum FGF-19. All patients and 14 healthy controls completed a diary recording, BSF, and stool frequency. RESULTS: We found that irritable bowel syndrome with diarrhea (IBS-D) n = 21/23 (91%) reported a high number on BSF ≥6, compared to patients with inflammatory bowel diseases (IBD) 56/77 (72%) with BSF ≥ 6 (P = .011). FGF-19 median serum levels were significantly lower in Microscopic colitis (0.010 pg/mL) and IBD patients (0.009 pg/mL) compare to IBS-D (266.9 pg/mL) and high levels in healthy subjects (463 pg/mL) (P < .001). Strong inverse correlation of FGF-19 with the stool frequency/day and stool index was found (r = -0.800, P < .001; r = -0.739, P < .001), independently from disease activity (r = -0.718, P = .001; r = -0.792, P = .001). CONCLUSION: Serum FGF-19 can become a new biomarker for evaluating the severity of diarrhea with objectively and independently from intestinal inflammation. FC and FGF-19 are predictive biomarkers for the organic cause of diarrhea.
BACKGROUND: In chronic diarrhea patients, massive over-reporting symptom-based criteria for functional bowel disorders are pitfalls. There is currently no objective biomarker that may provide a correct correlation with the severity of chronic diarrhea. To clarify the role of fibroblast growth factor-19 (FGF-19) as a biomarker of objective measurements of the severity of diarrhea in comparison with a patientreported outcome, based on the Bristol Stool Form (BSF) Scale. METHODS: Consecutive 100 patients with chronic diarrhea underwent standard investigations with laboratory tests, fecal calprotectin (FC), endoscopy with biopsies, and serum FGF-19. All patients and 14 healthy controls completed a diary recording, BSF, and stool frequency. RESULTS: We found that irritable bowel syndrome with diarrhea (IBS-D) n = 21/23 (91%) reported a high number on BSF ≥6, compared to patients with inflammatory bowel diseases (IBD) 56/77 (72%) with BSF ≥ 6 (P = .011). FGF-19 median serum levels were significantly lower in Microscopic colitis (0.010 pg/mL) and IBD patients (0.009 pg/mL) compare to IBS-D (266.9 pg/mL) and high levels in healthy subjects (463 pg/mL) (P < .001). Strong inverse correlation of FGF-19 with the stool frequency/day and stool index was found (r = -0.800, P < .001; r = -0.739, P < .001), independently from disease activity (r = -0.718, P = .001; r = -0.792, P = .001). CONCLUSION: Serum FGF-19 can become a new biomarker for evaluating the severity of diarrhea with objectively and independently from intestinal inflammation. FC and FGF-19 are predictive biomarkers for the organic cause of diarrhea.
Authors: Jonathan D Nolan; Ian M Johnston; Sanjeev S Pattni; Tracy Dew; Timothy R Orchard; Julian R F Walters Journal: J Crohns Colitis Date: 2015-02 Impact factor: 9.071
Authors: Luisa M ª Mena Bares; José M Benítez Cantero; Eva Iglesias Flores; Beatriz Gros Alcalde; Estefanía Moreno Ortega; Francisco R Maza Muret; Elvira Carmona Asenjo; M ª Valle García Sánchez; Juan A Vallejo Casas Journal: Rev Esp Enferm Dig Date: 2019-01 Impact factor: 2.086
Authors: Rian M Nijmeijer; Raffaella M Gadaleta; Saskia W C van Mil; Adriaan A van Bodegraven; J Bart A Crusius; Gerard Dijkstra; Daan W Hommes; Dirk J de Jong; Pieter C F Stokkers; Hein W Verspaget; Rinse K Weersma; C Janneke van der Woude; Janneke M Stapelbroek; Marguerite E I Schipper; Cisca Wijmenga; Karel J van Erpecum; Bas Oldenburg Journal: PLoS One Date: 2011-08-22 Impact factor: 3.240
Authors: Ramesh P Arasaradnam; Steven Brown; Alastair Forbes; Mark R Fox; Pali Hungin; Lawrence Kelman; Giles Major; Michelle O'Connor; Dave S Sanders; Rakesh Sinha; Stephen Charles Smith; Paul Thomas; Julian R F Walters Journal: Gut Date: 2018-04-13 Impact factor: 23.059
Authors: Fernando Magro; Paolo Gionchetti; Rami Eliakim; Sandro Ardizzone; Alessandro Armuzzi; Manuel Barreiro-de Acosta; Johan Burisch; Krisztina B Gecse; Ailsa L Hart; Pieter Hindryckx; Cord Langner; Jimmy K Limdi; Gianluca Pellino; Edyta Zagórowicz; Tim Raine; Marcus Harbord; Florian Rieder Journal: J Crohns Colitis Date: 2017-06-01 Impact factor: 10.020